Batten disease (also known as juvenile neuronal ceroid lipofuscinosis) is a recessively inherited neurodegenerative disorder of childhood characterized by progressive loss of vision, seizures, and psychomotor disturbances. The Batten disease gene, CLN3, maps to chromosome 16p12.1. The so-called 56 chromosome haplotype defined by alleles at the D'16S299 and D16S298 loci is shared by 73% of Batten disease chromosomes. Exon amplification of a cosmid containing D16S298 has yielded a candidate gene that is disrupted by a 1 kb genomic deletion in all patients carrying the 56 chromosome. Two separate deletions and a point mutation altering a splice site in three unrelated families have confirmed the candidate as the CLN3 gene. The disease gene encodes a novel 438 amino acid protein of unknown function.
Introduction
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigments (ceroid and lipofuscin) in neurons and other cell types (Dyken, 1988) . At least five subtypes are recognized, based on age of onset, clinicopathological features, and chromosomal location. Inheritance is autosomal recessive for the childhood onset forms, which include infantile (CLN1; HaltiaSantavuori disease, MIM256730), classical late infantile (CLN2; Jansky-Bielschowsky disease, MIM204500), juvenile (CLN3; Batten or Spielmeyer-Vogt-SjSgren disease, MIM304200), and Finnish-variant late infantile (CLN5; MIM256731). The primary biochemical defects in these disorders are not known.
Batten disease, the juvenile onset form of NCL, is the most common neurodegenerative disorder of childhood. Its incidence is estimated at up to 1 in 25,000 births (Zeman, 1974) , with an increased prevalence in the northern European populations. Clinical onset begins with visual failure between the age of 5 and 10 years. Seizures and mental deterioration ensue with relentless decline to death, usually in the second or third decade. Diagnostic criteria include the presence in many cell types of inclusions that appear as so-called fingerprint profiles on electron microscopy (Wisniewski et al., 1988) . The major protein component of these abnormal deposits is subunit 9 of mitochondrial ATPase (Palmer et al., 1992) , although the genetic defect does not lie in a gene encoding this 75 amino acid protein (Dyer and Walker, 1993; Yan et al., 1994) .
The loci for several NCL subtypes have been mapped by linkage analysis to different chromosomal regions. The gene for Batten disease, CLN3, was assigned to human chromosome 16 by demonstration of linkage to the haptoglobin locus (Eiberg et al., 1989) . A collaborative effort has allowed progressive refinement of the genetic localization of CLN3 (Gardiner et al., 1990; Callen et al., 1991; Yan et al., 1993; Mitchison et al., 1993; Lerner et al., 1994) with the aim of isolating the defective gene. Analysis of recombinations using a high resolution map of microsatellite marker loci has defined D16S288 and D16S383 as flanking markers and has thereby confined CLN3 to an interval of 2.1 cM in 16p12.1-11.2 (Mitchison et al., 1994) . Within this candidate region, four microsatellite loci, D16S288, D16S299, D16S298, and SPN, display strong linkage disequilibrium with CLN3 (Mitchison et al., 1993 (Mitchison et al., , 1994 (Mitchison et al., , 1995 Lerner et al., 1994) , and analysis of haplotypes on disease chromosomes suggests that CLN3 lies closest to D16S299 and D16S298 (see Figure 1) . A core 56 chromosome haplotype, based on the 5 allele at D16S299 and the 6 allele at D16S298, is present on 73% of disease chromosomes and on only 3% of control nondisease chromosomes. The 6 chromosome allele at D16S298 is present on 96% of Finnish Batten disease chromosomes, suggesting that CLN3 is close to this marker (Mitchison et al., 1995) . This is supported by the finding that two unusual patients have apparent deletions of D 16S298: a Moroccan patient (NCL39.3) from a consanguinous relationship homozygous for the absence of D16S298 as part of a cytogenetically undetectable microdeletion ) and a Finnish patient (L199Pa) hemizygous for D16S298 (Mitchison et al., 1995; this paper) .
We now report the identification of the Batten disease gene, defined by cDNA (clone 2-3), from a cosmid containing D16S298. The gene is disrupted by a small (1.02 kb) deletion on all Batten disease chromosomes with the 56 chromosome haplotype and by the independent deletions in the Finnish and Moroccan patients mentioned above. In another unrelated Batten disease family, we have identified a point mutation that segregates with the disease and alters an invariant base of a 5' donor splice site. The Batten disease gene, CLN3, possesses an open reading frame of 1314 bp encoding a predicted 438 amino acid protein product with no significant similarity to previously described proteins. The discovery of this disease gene will permit direct genetic diagnosis of Batten disease and represents an initial step to understanding the pathogenesis of this disorder.
Results

Isolation and Characterization of cDNA2-3
Previously, we described a cosmid walk from D16S48 in Los Alamos contig c343.1 (Stallings et al., 1992) toward D16S299, yielding the 185 kb contig cNL/343.1 (Figure 1 ). Cosmid NL11A, the most distal cosmid in this contig, was found to contain the D16S298 locus and to encompass the region deleted in the Moroccan patient NCL39.3. These findings implicate NL11A as the most likely site of CLN3. Thus, in this study, we targeted this cosmid for saturation with candidate Batten disease gene transcripts.
A 180 bp exon isolated from NLllA by exon amplification (Buckler et al., 1991; Church et al., 1994; Lerner et al., 1995) was used to screen a fetal brain cDNA library (Stratagene), yielding a 1.7 kb cDNA (clone 2-3). The re- suits of Southern blot and polymerase chain reaction (PCR) analyses of genomic and cosmid DNAs showed that the 1.7 kb cDNA is contained in NL11A and that transcription proceeds toward D16S299 (Figure 1 ). PCR amplification of individual Pstl fragments of NL11A using the D16S298 microsatellite primers placed D16S298 on a 1.3
kb Pstl fragment previously shown to be contained within the deletion of the Moroccan patient . This fragment is not detected by cDNA2-3, but consists of intron sequences mapping between bases 1193 and 1194 (see Figure 3 ) of the cDNA (H. M. M., unpublished data). Thus, cDNA2-3 spans the D16S298 locus and overlaps with the deletion found in the Moroccan patient. Northern blot analysis using cDNA2-3 as probe revealed a 1.7 kb transcript in poly(A) mRNA isolated from a wide variety of human tissues, including heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas ( Figure  2) , consistent with the cDNA clone being nearly full length. The transcript is not detected by Northern blot analysis in cultured lymphoblasts and in fibroblasts, but is detectable by reverse transcription PCR (RT-PCR) analysis of poly(A) mRNA isolated from such cell lines. A so-called zoo blot containing genomic DNAs from several animal species showed that this gene is conserved in mammals. Strong signals were obtained from mouse, sheep, cow, and pig (data not shown). Figure 3 shows the sequence of the cDNA that spans 1689 bp and has a 47 base poly(A) tail. A predicted open reading frame of 1314 bp begins with a potential initiator ATG codon at base 138 and ends with a TGA termination codon at base 1452. An in-frame stop codon is located 36 bases upstream of the initiator site, and a consensus polyadenylation site is located at base 1666. The predicted product of the cDNA is a protein of 438 amino acids with a molecular mass of 48 kDa.
Sequence Analysis of cDNA2-3
The cDNA sequence was compared against the GenBank and dbEST databases using BLASTN (Altschul et al., 1990) and FASTA (Pearson and Lipman, 1988) sequence alignment algorithms. These searches revealed no significant similarities to genes of known function. However, near identity (>95% similarity) was found to 13 expressed sequence tags (ESTs) (F11432, F12401, T74504, T08995, R12998, Z42735, T47968, D20292, T47969, T97772, F09095, F10019, and T61330) isolated from five independent cDNA libraries (infant brain, fetal spleen, fetal liver and spleen, adult liver, and promyelocyte cell line HL60). (Soares et al., 1994) , are missing bases 184-262 of cDNA2-3 ( Figure 3 ). If the same initiator ATG is used, this transcript is expected to produce a truncated protein of only 27 amino acids and, thus, is unlikely to be the result of normal RNA splicing. The physiological significance of this variant is unclear, since its relative abundance may be exaggerated by preparation of the normalized cDNA library.
The predicted protein sequence was compared against the SwissProt database using BLASTP and Smith-Waterman (Smith and Waterman, 1981) sequence alignment algorithms and against the predicted translation products of GenBank database using TBLASTN. In all these cases, no significant similarities were found to known proteins. A search of the BLOCKS database (version 8.0; Henikoff and Henikoff, 1994) for motifs found only single blocks of homology for any group of proteins, and this could be attributed to chance. A search for protein motifs in the CLN3 protein using the ProSite Database (version 12.2) revealed pattern matches for four N-glycosylation sites, two glycosaminoglycan attachment sites, two cAMP-and cGMP-dependent protein kinase phosphorylation sites, six protein kinase C phosphorylation sites, eight casein kinase II phosphorylation sites, and 12 N-myristoylation sites ( Figure 3 ). Hydropathy calculations (Kyte and Doolittie, 1982) predicted five hydrophobic regions that may be potential membrane-spanning regions at amino acids 38-61, 93-233, 278-310, 345-399, and 408-438 .
The Common Mutation Is A Small Deletion
To screen for possible deletions, insertions, and other chromosomal rearrangements associated with the clone 2-3 gene, we scanned conventional Southern blots of restriction-digested DNA from unrelated Batten disease patients. Figure 4a The predicted protein is shown below the DNA sequence, assuming that translation begins at the first in-frame methionine of the long open reading frame. Four potential N-linked glycosylation sites are indicated by a broken line at residues 49, 71, 85, and 310 (Bause, 1983) . Two potential glycosaminoglycan sites are indicated by the dotted lines at residues 162 and 186 (Bourdon et al., 1987) . Potential N-myristoylation sites are indicated by a number sign (Grand, 1989) . Serine and threonine residues that are potentially phosphorylated by cAMP-and cGMPdependent protein kinases (indicated by a percent sign) (Glass et al., 1986) , by protein kinase C (indicated by an asterisk) (Woodgett et al., 1986) , or by casein kinase II (indicated by a caret) (Pinna, 1990) are shown. The polyadenylation site at base 1666 is indicated by a dollar ment was used as probe, no difference was detected between controls and the homozygous 56 chromosome haplotype affected patients. Analysis of 148 control chromosomes, including seven with the 56 chromosome hapIotype, revealed no alterations. The affected individuals bearing a 56 chromosome also displayed altered fragments with Hindlll and Pvull digestion (data not shown), suggestive of a small (-1000 bp) genomic deletion of the 56 chromosome. Figure 4b illustrates the Mendelian inheritance of this deletion in a two-generation Batten disease family segregating the 56 chromosome haplotype.
To determine the effect of this genomic deletion on the clone 2-3 transcript, we performed PCR amplification of RT cDNA from patients homozygous for the 56 chromosome haplotype. The P1-P3 primer pair yielded a novel product that was -200 bp smaller than that predicted from the cDNA sequence and that was found in all non-56 chromosome normal controls (Figure 4c ). RT-PCR amplification with the P2-P5 primer pair yielded identical -800 bp products in affected patients and controls. DNA sequence analysis of the P1-P3 product from five homozygous 56 chromosome patients showed in all cases a 217 bp deletion, from base 598 to base 814 of the cDNA (see Figure 3) . The DNA sequence of the RT cDNA from four control individuals revealed no evidence of deletion, matching the cDNA2-3 sequence. Deletion of these 217 bases of coding sequence produces a frameshift, generating a TAA termination codon 84 bp downstream of the deletion junction. The predicted translation product is a truncated protein of 181 amino acids consisting of the first 153 residues of the protein followed by 28 novel amino acids before the stop codon.
DNA sequence analysis of the genomic fragment containing this deletion from a 56 chromosome homozygous patient revealed the loss of 1.02 kb of genomic sequence (Figure 5a ). The intron sequence immediately 5' to the deletion is 91% homologous to bases 84-290 of the AluSx family consensus sequence in the 5' to 3' orientation. The A-rich sequence at the 3' end of this Alu sequence includes a (GA)n repeat within the 5' deleted segment. The sequence at the 3' portion of the deleted region is 87% homologous to bases 1-290 of the Alu-Sx sequence, also in the 5'to 3' orientation, and contains a (GA)o repeat within the A-rich sequence of the 3' tail. Included in this deletion are 217 bp of the open reading frame (base pairs 598-814; see Figure 3 ), corresponding to two exons.
Screening for the 56 Chromosome Deletion
PCR amplification of genomic DNA with primers F2 and P3 flanking the cDNA deletion produces a 3.5 kb product from normal chromosomes and a 2.5 kb product from the chromosomes with the 1.02 kb deletion described above.
sign. cDNA sequences deleted in the 56 chromosome deletion (bases 598-814) and the L199Pa deletion (bases 928-1193) Figure 4, Analysis of cDNA2-3 in Batten Disease Patients (a) Southern blot analysis of cDNA2-3 in Batten disease patients. Genomic DNA was digested with Pstl, subjected to agarose gel electrophoresis, and transferred to Hybond N ÷ membrane (Amersham). Lanes 1-3, patients homozygous for the 56 chromosome alleles; lane 4, unaffected control; lane 5, patient heterozygous for the 56 chromosome alleles (see text for data on patient L199Pa). The left panel was probed with a radiolabeled PCR fragment amplified from cDNA2-3 using primers P1-P3, corresponding to the 5' half of the cDNA. The right panel was probed with a radiolabeled PCR fragment amplified from cDNA2-3 using primers P2-P5, corresponding to the 3' half of the cDNA. (b) Southern blot analysis of cDNA2-3 in a family with an affected child homozygous for the 56 chromosome haplotype. Southern blots were prepared as described above and hybridized with the P1-P3 probe• The affected individual is shown by the closed symbol and carriers by the half-closed symbols. Progeny are shown by diamonds, and the birth order of some individuals has been changed for confidentiality. The chromosomes segregating in this pedigree have been distinguished by extensive typing with polymorphic markers in 16p12.1-11.2 .
We tested for the presence of the 1.02 kb deletion associated with the D16S299/D16S298 56 chromosome haplotype in 81 unrelated Batten patients representing 24 haplotypes and originating from 16 countries (Table 1) . Of these, 46 were homozygous for the 56 chromosome haplotype, 24 were heterozygous for the 56 chromosome haplotype, and 11 did not carry the 56 chromosome haplotype on either chromosome. In all 70 patients with an affected 56 chromosome, the 2.5 kb fragment was detected, and in all 46 homozygotes for this haplotype, no normal size product was produced. Smaller numbers of chromosomes bearing closely related haplotypes (66, 36, 46, 57, and 55) also carried this deletion, suggesting that these chromosomes most probably derived from the 56 chromosome haplotype by mutation of the polymorphic marker or recombination. Additional affected chromosomes bearing the 66 and 46 chromosome haplotypes apparently possess mutations independent of the 56 chromosome, as they do not carry this deletion. Thus, the 1.02 kb genomic deletion of the clone 2-3 gene associated with the 56 chromosome haplotype is the most common mutation in Batten disease, accounting for 81% of disease chromosomes tested to date.
Other Mutations Disrupting the Gene
Haplotype analysis of Finnish patient L199Pa revealed one 56 chromosome and one @null chromosome, exhibiting absence of any D16S298 allele (for clinical details see Experimental Procedures). Southern blot analysis of this patient (see Figure 4a , lane 5) revealed two alterations: the 1.02 kb deletion typical of the 56 chromosome haplotype and a second deletion present on the chromosome missing D16S298 that results in the formation of a novel 1.5 kbjunction fragment. This junction fragment combines sequences from an upstream 1.1 kb Pstl fragment detected by the cDNA probe and from a Pstl fragment 3' to D16S298 that contains only intron sequence. PCR analysis of patient DNA using the i ntron primer IntR 14 and cDNA primer F9 confirmed an -3 kb deletion, including the entire 1.3 kb Pstl fragment containing D16S298 (Figure 5b ). RT cDNA from this second mutant allele was selectively amplified using primer R5 and primer FS, which is deleted on the 56 chromosome. The amplified product revealed the absence of 266 bp of coding sequence between bases 928 and 1193 of the cDNA (see Figure 3) , generating a TGA termination codon 84 bp downstream of the deletion junction. The predicted translation product is a truncated protein of 291 amino acids consisting of the first 263 amino acids of the protein followed by 26 novel amino acids before the stop codon. Partial DNA sequence analysis of the genomic fragment containing this -3 kb deletion has confirmed the loss of bases 928-1193 of the cDNA. We previously described a homozygous deletion of the D16S298 locus in a Batten patient of Moroccan origin (NCL39.3). Although the size of the deletion was not determined, it did include the 1.3 kb Pstl fragment containing D16S298 , which has proved to Other haplotypes + -1 -+
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Genomic PCR was carried out using primer pair F2-P3 at bases 552 and 880 of the cDNA2-3 sequence. PCR amplification was carried out as described in Experimental Procedures. a Total number of chromosomes was 162.
be within an intron of the clone 2-3 candidate gene. PCR amplification of genomic DNA with primers F2 and R3 yielded a 1.1 kb fragment instead of the expected -7 kb fragment (Figu re 5b). Additional PCR amplifications using nested primers on either the 5' (F4-R3) or 3' (GF1-GR1) sides gave no product, suggesting a deletion in the Moroccan patient of -6 kb that starts between F2 and F4 and ends between GF1 and R3. Single-stranded conformation polymorphism (Orita et al., 1989) was performed to scan the CLN3 gene for further mutations. Patient L198Pa (for clinical details see Experimental Procedures), who is heterozygous with one 56 chromosome and one 76 chromosome (D16S299/D16S298), exhibited a mobility shift in a 73 bp exon corresponding to bases 598-670 of the cDNA (data not shown). Nucleotide sequence analysis showed a G to C transition at +1 of the splice donor site following the exon. Analysis of the parents of patient L198Pa showed the father (haplotype 76•46) to be a heterozygous carrier of this mutation.
Discussion
The results of haplotype analysis of 142 families suggested that the major Batten disease mutation occurred on an ancestral chromosome bearing the D 16S299/D 16S298 56 chromosome haplotype (Mitchison ~pt al., 1994) . The data presented here provide compelling evidence that this mutation is a 1.02 kb deletion that implicates cDNA2-3 as the product of CLN3. This deletion involves the 3' end of two Alu-Sx elements and the following (GA)o sequence and may therefore have arisen by recombination involving bordering Alu sequences, a mechanism for which other examples exist in human disease (e.g., Rudiger et al., 1995) . The deletion mutation is found on all affected 56 chromosomes examined to date and on several chromosomes with related haplotypes, accounting for 81% of Batten disease chromosomes.
Studies are in progress to characterize the mutations of the clone 2-3 gene found on the minority of disease chromosomes that do not carry the 1.02 kb deletion. With the notable exceptions of patients L199Pa and NCL39.3, Southern blot and long-range PCR analyses of patients with chromosomes lacking the 1.02 kb deletion have failed to reveal additional genomic rearrangements. These results suggest that these affected chromosomes most likely carry point mutations, small deletions, or regulatory mutations of CLN3, e.g., the altered splice site in patient L198Pa. The independent deletions in L199Pa and NCL39.3, both of which encompass the D16S298 microsatellite locus, provide the strongest confirmatory evidence that cDNA2-3 is the product of CLN3. Ultimate proof, however, that cDNA2-3 represents CLN3 will require the reversal of the disease phenotype in a cell or animal model system or the generation of knockout animals that exhibit a Batten disease-like phenotype.
No homology has been found at the nucleotide or amino acid level with any previously identified gene, indicating that CLN3 encodes a novel protein of (as yet) unknown function. Diverse approaches may now be used to explore the normal physiological role of the CLN3 protein. For example, the conservation of coding sequences across species should allow the identification of homologous sequences and target conserved domains of functional significance. The presence of several potential phosphorylation sites suggests that the protein may undergo phosphorylation as a prerequisite for binding an additional protein(s). The PSORT program (version 6.3; Nakai and Kanehisa, 1992) for prediction of protein localization sites indicates that the CLN3 protein may be a type IIIb membrane protein (Heijne and Gavel, 1988) , a possibility supported by hydropathy calculations that suggest the presence of several hydrophobic domains and by numerous potential N-glycosylation and N-myristoylation sites.
The deletions identified to date are predicted to remove >100 amino acids from the C-terminal portion of the CLN3 protein, suggesting that its normal function would be severely compromised in the disease. However, it is also conceivable that the disease phenotype may involve abnormal accumulation of truncated protein products rather than or in addition to direct loss of protein function. The CLN3 gene is expressed not only in the brain, the site of massive neuronal cell death in Batten patients, but also in a wide range of tissues. Consistent with this, inclusion bodies have been found in many Batten disease tissues in addition to the brain. Palmer et al. (1992) demonstrated the abnormal accumulation of subunit 9 of mitochondrial ATPase in these inclusions, but experiments mapping the subunit 9 genes P1 and P2 to chromosomes 17 and 12, respectively (Dyer and Walker, 1993) , and P3 to chromosome 2 (Yan et al., 1994) excluded these genes as the site of the Batten disease defect. It will now be of interest to determine whether the CLN3 protein or fragments thereof also accumulate in the disorder. Similarly, various biochemical approaches have suggested that Batten disease involves perturbations in several metabolic pathways, including, for example, lipid peroxidation (Siakotos et al., 1988) , metabolism of dolichol-linked oligosaccharides (Hall and Patrick, 1985) , and lysosomal proteinase activity (Wolfe et al., 1987) . Whether these diverse biochemical phenotypes are the result of the primary gene defect or are secondary effects of the disease process can now be examined.
Because of the slow progression of symptoms in Batten disease and its similarity to other NCL subtypes and neurologic disorders, diagnosis is often missed or delayed. Current diagnostic protocols call for examination of skin biopsies for hallmark fingerprint profiles in inclusion bodies, a technically demanding procedure. Since the demonstration of linkage disequilibrium, carrier detection by haplotype analysis has been possible (Taschner et al., 1995b) . The direct PCR assay for the 56 chromosome deletion described in this paper will imp.rove the reliability of the diagnosis for the majority of Batten disease patients and provide families with the opportunity for prenatal and carrier testing.
The identification of the Batten disease gene is the initial step in understanding the pathology underlying this complex disorder. This study provides the basis for analyzing the role of the CLN3 protein in both normal and disease cells and provides a starting point for the design of rational therapies. Moreover, what we learn from studying the CLN3 protein may reveal the underlying cause of the other ceroid lipofuscinoses and provide insights into the mechanisms involved in other neurodegenerative disorders.
Experimental Procedures
Patients and Cell Lines
Patients with Batten disease were identified through contacts with organizations of volunteer parents and through clinical referrals. Diagnoses were confirmed using standard criteria (Boustany et al., 1988; Santavuori, 1988) . The establishment of lymphoblastoid cell lines was previously described (Anderson and Gusella, 1984) . Finnish patient L199Pa had a normal birth and early childhood. At age 6.5, he was referred to Dr. P. Santavuori at the University of Helsinki Clinic and Children's Hospital because of failing vision. Electroretinogram was abolished, and visual evoked potential was abnormal with delayed latency. Slight motor clumsiness and muscular hypotonia were found. Vacuolated lymphocytes were positive on repeated examinations. From age 11, he had generalized epileptic seizures that were well controlled by sodium valproate-clonazepam. An MRI at age 16 showed slight central, cortical, and cerebellar atrophy. The patient is still able to walk independently, but jumping has become difficult. He has finished school and is working in a daycare center.
Finnish patient L198Pa had an uneventful birth and early childhood. Since the age of 7, she has experienced progressive visual failure. At age 9, she showed an abnormal MRI. Vacuolated lymphocytes were repeatedly observed, and electron microscopy of a rectal biopsy specimen showed inclusions typical for Batten disease. She has been on sodium valproate medication since the age of 9, when she experienced her only seizure. Recent examination at the age of 13 showed that her motor status is good but that her mental decline has been relatively fast.
The Moroccan patient has been previously described .
DNA Electrophoresis and Hybridization
DNA extraction, restriction digests, electrophoresis, Southern blotting, hybridization, and washing were performed by standard methods (Sambrook et al., 1989) .
cDNA Screening and Characterization
Exon amplification was carried out using the pSPL3 vector as described by Church et al. (1994) . A human fetal brain cDNA library in Z7_.APII (Stratagene) was screened by standard methods using exon probes, cDNA clones and trapped exons were sequenced manually (Sanger et al., 1977) with Sequenase T7 DNA polymerase (United States Biochemicals).
RNA Procedures
Cytoplasmic RNA was isolated by standard methods (Sambrook et al., 1989) or using RNazol (Biogenesis). RNA was reverse transcribed using oligo(dT) or random hexamer primers and Superscript reverse transcriptase (GIBCO). Portions of the cDNA were amplified using primer sets described in the text. Direct sequencing of PCR products was carried out as described previously (McClatchey et al., 1992) or by purification with Qiagel (Qiagen) followed by sequencing with an Applied Biosystems (ABI) 373A automated sequencer. PCR products were subcloned using the TA cloning kit (Invitrogen).
PCR
PCR was carried out using Taq polymerase, following the recommendations of the manufacturer. The assay for the 56 chromosome deletion was carried out on 100 ng of genomic DNA using primers F2 and P3 in a reaction including 0.2 p.M of each primer, 0.2 mM of each dNTP, 1.5 mM MgCI2, and 0.5-1 I~1 of AmpliTaq (Perkins-Elmer). In one laboratory, the reaction was supplemented with 5 U of TaqExtender (Stratagene), which was found to enhance the amplification. Annealing temperatures ranging between 55°C and 62°C were used successfully. Samples were fractionated on an 0.8% agarose gel.
Genomic Sequencing
Genomic DNA from a normal control and the somatic cell hybrid CY101, which carries a single copy of chromosome 16 derived from a patient homezygous for the 56 chromosome hapletype, was PCR amplified with primers P1-P3. The resulting PCR products were digested with Taql. A 1.5 kb fragment was detected in the control, and a 0.5 kb fragment was detected in CY101, These two fragments were subcloned into pUC19 and sequenced with an ABI 373A automated sequencer, In an independent study, the sequence spanning the 56 chromosome deletion was generated by PCR sequencing of the subcloned 3.8 kb Pstl fragment using an AB1373A automated sequencer.
Single-Stranded Conformation Polymorphism Analysis
Intron primers IntF6 (5'-GGAGCCTCTATGAGCTGATACTG-3') and IntR12 (5'-GGAACATTCAGGAGGACCTAGG-3') were used to amplify patient DNA for single-stranded conformation polymorphism analysis (Orita et al., 1989) . Each sample (-0.5 p.I) was loaded onto 12,5% homogeneous gels, and these were electrophoresed for -200 vh at 15°C in a PhastSystem apparatus (Pharmacia). Gels were subsequently stained and fixed using the method suggested bythe manufacturer. The patient sample exhibiting a band shift was sequenced using the Taq dye deoxy terminator cycle sequencing kit and analyzed using the ABI 373A sequencer.
